相关实验视频

Updated: Jun 23, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

用Bcl-2修改的仿真抗原受体对增强的固体瘤向的协同效应

Xiaoyan Wang¹, Guodong Liu², Tian Huan³

¹Department of Gastroenterology, Suqian First People's Hospital, Suqian, 223800, Jiangsu, China.

|June 15, 2024

概括

针对皮肤生长因子受体变异III (EGFRvIII) 的工程T细胞与B细胞淋巴瘤2 (Bcl-2) 增强,以改善固体瘤治疗. 这些经过修改的CAR T细胞表现出优异的持久性和抗瘤活性.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
生物技术是生物技术.

背景情况:

化学抗原受体 (CAR) T细胞在血液癌症中表现出有效性,但在固体瘤中面临挑战.
弱的CAR T细胞持久性,可能是由于激活诱导的细胞死亡 (AICD),限制了它们对固体瘤的有效性.

研究的目的:

通过提高CAR T细胞的持久性和抗亡性质,增强CAR T细胞对固体瘤的治疗潜力.
为了研究用针对皮肤生长因子受体 III 变异 (EGFRvIII) 的抗亡分子 B 细胞淋巴瘤 2 (Bcl-2) 进行工程的 CAR T 细胞的疗效.

主要方法:

工程CAR-T细胞向EGFRvIII,以共同表达Bcl-2,从而产生EGFRvIII·CAR-T-Bcl2细胞.
与EGFRvIII·CAR-T细胞相比,EGFRvIII·CAR-T-Bcl2细胞的增殖,抗亡和瘤细胞杀伤能力的体外评估.
在宫癌异种移植模型中对EGFRvIII·CAR-T-Bcl2细胞的抗瘤作用和持久性的体内评估.

主要成果:

EGFRvIII·CAR-T-Bcl2细胞在体外表现出增强的增殖,对细胞灭绝的抵抗力和优异的瘤细胞杀伤能力,与对照的CAR T细胞相比.
在临床前的宫癌模型中,EGFRvIII·CAR-T-Bcl2细胞表现出长时间的持久性和改善的抗瘤疗效.
加入Bcl-2显著增加了EGFRvIII向的CAR T细胞的功能能力和治疗影响.

结论:

将像Bcl-2这样的抗亡分子纳入CAR T细胞是克服固体瘤治疗局限性的可行策略.
通过基因改造增强CAR T细胞的持久性和功能可以改善固体恶性瘤的治疗结果.
EGFRvIII·CAR-T-Bcl2细胞代表了对固体瘤的CAR-T细胞疗法的有前途的进步,特别是那些表达EGFRvIII的瘤.

关键词:

在AICD中,AICD是AICD.Bcl-2 的使用方法.汽车车上的车辆.欧洲农业基金第八.固体瘤是一个固体瘤.

更多相关视频

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...